Catalyst Biosciences Inc
NASDAQ:CBIO
Intrinsic Value
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one
CBIO
stock under the Base Case scenario is
0.4391
USD.
Compared to the current market price of 0.5113 USD,
Catalyst Biosciences Inc
is
Overvalued by 14%.
Catalyst Biosciences Inc's market capitalization is 289.6m USD.
CBIO stock price is 7.6695 USD.
CBIO stock (0.4391 USD) is 94% less than its price (7.6695 USD).
CBIO stock (0.5738 USD) is 93% less than its price (7.6695 USD). Open DCF Valuation
CBIO stock (0.3044 USD) is 96% less than its price (7.6695 USD). Open Relative Valuation
CBIO.
CBIO has negative Gross Profit for the last twelve months.
CBIO's long-term assets (10m USD) exceed its long-term liabilties (6m USD).
CBIO's Revenue has dropped by 89% over the past 12 months.
CBIO has negative Operating Income for the last twelve months.
CBIO has negative Net Income for the last twelve months.
CBIO's short-term assets (5m USD) exceed its short-term liabilties (2m USD).
CBIO has negative Free Cash Flow for the last twelve months.
Valuation Backtest
Catalyst Biosciences Inc
Run backtest to discover the historical profit from buying and selling
CBIO
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Catalyst Biosciences Inc
Balance Sheet Decomposition
Catalyst Biosciences Inc
Catalyst Biosciences Inc
Earnings Waterfall
Catalyst Biosciences Inc
|
Revenue
|
794k
USD
|
|
Cost of Revenue
|
-798k
USD
|
|
Gross Profit
|
-4k
USD
|
|
Operating Expenses
|
-29.4m
USD
|
|
Operating Income
|
-29.4m
USD
|
|
Other Expenses
|
21.2m
USD
|
|
Net Income
|
-8.2m
USD
|
Free Cash Flow Analysis
Catalyst Biosciences Inc
CBIO Profitability Score
Profitability Due Diligence
Catalyst Biosciences Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Catalyst Biosciences Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
CBIO Solvency Score
Solvency Due Diligence
Catalyst Biosciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Catalyst Biosciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CBIO Price Targets Summary
Catalyst Biosciences Inc
Ownership
CBIO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CBIO Price
Catalyst Biosciences Inc
| Average Annual Return | -38.82% |
| Standard Deviation of Annual Returns | 40.48% |
| Max Drawdown | -96% |
| Market Capitalization | 289.6m USD |
| Shares Outstanding | 37 759 800 |
| Percentage of Shares Shorted | 0.11% |
CBIO News
Last Important Events
Catalyst Biosciences Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Catalyst Biosciences Inc
Company Profile
Catalyst Biosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2006-04-12. The firm is focused on developing protease therapeutics to address unmet medical needs in disorders of the complement system or where complement components are associated with the progression of the disease state. Its pipeline consists of a preclinical complement component 3 (C3) degrader program for geographic atrophy (GA) in dry age-related macular degeneration (dAMD), an improved Complement Factor I (CFI) protease, CB 4332, for subcutaneous (SQ) or intravitreal (IVT) therapy to restore complement homeostasis in diseases of overactive complement or CFI deficiencies, and proteases from our ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways. The Company’s portfolio consists of development candidates, which include CB 4332 and CB 2782-PEG.
Contact
IPO
Employees
Officers
The intrinsic value of one
CBIO
stock under the Base Case scenario is
0.4391
USD.
Compared to the current market price of 0.5113 USD,
Catalyst Biosciences Inc
is
Overvalued by 14%.
You don't have any saved screeners yet
